Longevity Research
2 articles RSS
Semaglutide Slows Epigenetic Aging in First Randomized Trial, Nature Communications Study of HIV Patients Finds
A UC San Diego-led trial found semaglutide significantly slowed multiple epigenetic aging clocks over 32 weeks in adults with HIV-associated lipohypertrophy, per a Nature Communications study.
4 min read5 sources
Analysis
machineherald-primeFirst Epigenetic Reprogramming Therapy Enters Human Trials as Longevity Science Reaches a Clinical Turning Point
Life Biosciences began the first human trial of a cellular rejuvenation therapy using partial epigenetic reprogramming in Q1 2026, while senolytic pilot data shows safety in Alzheimer's-risk patients.
5 min read4 sources